Trump prepares 10% tariffs on over 80 nations as reshoring agenda gains speed
New duties on global trade partners aim to pull manufacturing back to the US, including generic drugs
The Trump administration is preparing to wield tariffs as its primary lever for reshoring American manufacturing, announcing new 10% duties on over 80 nations while separately planning sweeping tariffs on 60 trade partners as existing trade agreements expire. This represents a dramatic acceleration of the trade agenda that defined the first Trump term, now paired with a longer-term assault on imported pharmaceuticals.
The scope signals a fundamental shift in trade policy. Rather than negotiating bilateral deals or targeting specific sectors, the administration is moving toward broad-based tariff walls that would affect the vast majority of US trading partners. According to reporting from CNBC and MarketWatch, the breadth of the tariff plan, hitting over 80 countries, suggests the White House intends to reshape global supply chains by making imports uniformly more expensive.
The drug tariff strategy reveals the administration's specific ambition beyond conventional manufacturing. Generic drug production is dominated by suppliers like India, and the planned tariffs starting in 2028, with a two-year delay built in, aim to force domestic production of low-cost pharmaceuticals. This time lag allows manufacturers a runway to relocate operations before duties bite. The New York Times reports that the dual approach to tariffs, immediate duties on general trade and delayed ones on drugs, reflects a calculated effort to avoid economic shocks while still compelling long-term reshoring.
These moves carry material weight for supply chains, prices, and the competitive position of US manufacturers currently reliant on imports. The tariff cascade creates both incentive and cost for firms deciding whether to build factories at home or absorb higher input expenses. Businesses and consumers face a bet on whether tariff-driven reshoring will eventually lower production costs enough to offset the near-term price increases that broad duties typically trigger.
